Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Odronextamab |
| Synonyms | |
| Therapy Description |
Odronextamab (REGN1979) is a CD20/CD3 bispecific antibody, which targets CD20 expressing cells via T-cell activation, and subsequently leads to cell death (PMID: 26659273). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Odronextamab | REGN1979 | Odronextamab (REGN1979) is a CD20/CD3 bispecific antibody, which targets CD20 expressing cells via T-cell activation, and subsequently leads to cell death (PMID: 26659273). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06097364 | Phase III | Rituximab Cyclophosphamide + Doxorubicin + Odronextamab + Prednisone + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate Odronextamab Cyclophosphamide + Odronextamab + Prednisone + Vincristine Sulfate | A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma (OLYMPIA-2) | Recruiting | USA | TUR | POL | ITA | ISR | GBR | FRA | ESP | CZE | BEL | AUT | AUS | 3 |
| NCT05991388 | Phase II | Carboplatin + Dexamethasone + Etoposide + Ifosfamide + Loncastuximab tesirine-lpyl + Rituximab Odronextamab Carboplatin + Dexamethasone + Etoposide + Ifosfamide + Rituximab | A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma (Glo-BNHL) | Recruiting | GBR | 0 |
| NCT06091254 | Phase III | Odronextamab Cyclophosphamide + Prednisone + Rituximab + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate Bendamustine + Rituximab | A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Participants With Follicular Lymphoma (OLYMPIA-1) | Recruiting | USA | TUR | POL | ITA | ISR | GBR | FRA | ESP | DEU | CZE | CHE | CAN | BRA | AUT | AUS | 2 |
| NCT03888105 | Phase II | Odronextamab | Assess the Anti-Tumor Activity and Safety of REGN1979 in Patients With Relapsed or Refractory Follicular Lymphoma | Recruiting | USA | POL | ITA | GBR | FRA | ESP | DEU | CAN | AUS | 5 |
| NCT06854159 | Phase II | Odronextamab | Odronextamab for the Treatment of Relapsed and Refractory Diffuse Large B-cell Lymphoma Before and After Chimeric Antigen Receptor T-cell Therapy | Not yet recruiting | USA | 0 |
| NCT06230224 | Phase III | Carboplatin + Etoposide + Ifosfamide Carboplatin + Etoposide + Ifosfamide + Rituximab Cisplatin + Dexamethasone + Gemcitabine + Rituximab Cisplatin + Cytarabine + Dexamethasone Cisplatin + Dexamethasone + Gemcitabine Odronextamab Cisplatin + Cytarabine + Dexamethasone + Rituximab | A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma (OLYMPIA-4) | Recruiting | TUR | NLD | ITA | ESP | AUS | 5 |
| NCT06784726 | Phase II | Odronextamab | Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T | Not yet recruiting | USA | 0 |
| NCT02290951 | Phase I | Rituximab Odronextamab | Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignancies (ELM-1) | Active, not recruiting | USA | ISR | GBR | FRA | DEU | 0 |
CKB BOOST